Abstract
The chemical nonhormonal treatment of breast cancer has developed rapidly in the last three decades. In the first two decades, several reports indicated that responses could be achieved in patients with nitrogen mustard,(1) triethylenethiophosphoramide (thio-TEPA),(2) methotrexate,(3) cyclophosphamide,(4,5) and 5-fluorouracil.(6) With the demonstration in experimental animal tumors and clinically in patients with Hodgkin’s disease(7) and acute lymphocytic leukemia(8) that combinations of drugs were more effective than single agents, interest in the use of multiple-drug regimens also developed for patients with breast cancer. One of the earliest reports was by Greenspan et al. in 1963.(9) But it was not until 1969, when Cooper(10) reported that a five-drug program produced complete responses in 90% of patients with advanced breast cancer, that the trials with combination chemotherapy became more widespread. Since then, there has been a literal explosion of combination chemotherapy programs(11) producing high response rates in the 50–60% range. In the past two years, chemotherapy has played a major role combined with surgery in the management of primary operable breast cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
C. Rhoads, Report on a cooperative study of nitrogen mustard (HN2) therapy of neoplastic disease, Trans. Assoc. Am. Physicians 60, 110–117 (1948).
C.G. Zubrod, M. Schneiderman, E. Frei, III, C. Brindley, G.L. Gold, B. Shnider, R. Oviedo, J. Gorman, R. Jones Jr., U. Jonsson, J. Colsky, T. Chalmers, B. Ferguson, M. Dederick, J. Holland, O. Selawry, W. Regelson, L. Lasagna, and A.H. Owens Jr., Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylenethiophosphoramide, J. Chronic Dis. 11, 7–33 (1960).
E.B. Schoenbach, J. Colsky, and E.M. Greenspan, Observations on the effects of the folic acid antagonists, aminopterin and amethopterin, in patients with advanced neoplasms, Cancer 5, 1201–1220 (1952).
R.W. Rundles, J. Laszlo, F.E. Garrison, and J.B. Hobson, The antitumor spectrum of cyclophosphamide, Cancer Chemother. Rep. 16, 407–411 (1962).
H. Atkins, H.G. Gregg, and G.A. Hyman, Clinical appraisal of cyclophosphamide in malignant neoplasms, Cancer 15, 1076–1080 (1962).
F. Ansfield, J. Schroeder, and A. Curreri, Five years clinical experience with 5-fluorouradl, J. Am. Med. Assoc. 181, 295–299 (1962).
V.T. DeVita, A.A. Serpick, and P.P. Carbone, Combination chemotherapy in the treatment of advanced Hodgkin’s disease, Ann. Intern. Med. 73, 881–895 (1970).
J. Simone, R.A.J. Aur, H.O. Hustu, and D. Pinkel, Total therapy studies of acute lymphocytic leukemia in children, Cancer 30, 1488–1494 (1972).
E.M. Greenspan, M. Fieber, G. Lesnick, and S. Edelman, Response of advanced breast carcinoma to the combination of the antimetabolite, methotrexate, and the alkylating atent, thio-TEPA, J. Mt. Sinai Hosp. N.Y. 30, 246–267 (1963).
R.J. Cooper, Combination chemotherapy in hormone resistant breast cancer, Proc. Am. Assoc. Cancer Res. 10, 15 (1969).
L. Broder and D.C. Tormey, Combination chemotherapy of carcinoma of the breast: A review, Cancer Treat. Rev. 1, 183–203 (1974).
P.P. Carbone, The role of chemotherapy in treatment for breast cancer, in: Cancer Chemotherapy—Fundamental Concepts and Recent Advances (M.D. Anderson Hospital, ed.), pp. 311–322, Year Book Medical Publishers, Inc., Chicago (1975).
L.M. Axtell and M.H. Myers, Recent trends in survival of cancer patients 1960–1971, End Results in Cancer Report #4, DHEW Publication (NIH) (1975), #767.
D.C. Tormey and J.P. Neifeld, Chemotherapeutic approaches to disseminated breast cancer, in: Breast Cancer Management—Early and Late (B.A. Stoll, ed.) (1977), in press.
S.J. Cutler, Classification of extent of disease in breast cancer, Semin. Oncol. 1, 91–96 (1974).
B. Fisher, R.G. Ravdin, and R.K. Ausman, Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation, Ann. Surg. 168, 337–356 (1968).
S.G. Taylor, III, S.J. Pocock, B.I. Shnider, J. Colsky, and T.C. Hall, Clinical studies of 5-fluorouracil + premarin in the treatment of breast cancer, Med. Pediatr. Oncol. 1, 113–121 (1975).
D.C. Tormey, P. Band, and M. Bauer for the Eastern Cooperative Oncology Group, Results of analyses of combination chemotherapy trials (1976) (unpublished).
J. Ingle, D.C. Tormey, and J. Bull. Bone marrow involvement in breast cancer, Proc. Am. Soc. Clin. Oncol. 16, 245 (1975).
S.J. Cutler, A.J. Asire, and S.G. Taylor, III, Classification of Patients with disseminated cancer of the breast, Cancer 24, 861–869 (1969).
M. Cutler, Local extension and distant metastases, in: Tumors of the Breast, pp. 124–147, J.B. Lippincott Co., Philadelphia (1962).
M.M. Romsdahl, M.E. Sears, and N.E. Eckles, Post treatment evaluation of breast cancer, in: Breast Cancer: Early and Late (M.D. Anderson Hospital, ed.), pp. 291–299, Year Book Medical Publishers, Inc., Chicago (1970).
S.M. Levenson, J.J. Ingle, S.D. Richman, R.S. Frankel, D.C. Tormey, A.E. Jones, and G.S. Johnston, Liver scanning in metastatic carcinoma of the breast, J. Nucl. Med. 16, 545 (1975).
D.C. Tormey and J.N. Ingle, Diagnostic considerations in breast cancer, in: Breast Cancer Diagnosis (G.S. Johnston and A.E. Jones, eds.), pp. 1–17, Plenum Medical Book Co., New York (1975).
S.D. Richman, J.N. Ingle, S.M. Levenson, J.P. Neifeld, D.C. Tormey, A.E. Jones, and G.S. Johnston, The usefulness of gallium scintigraphy in primary and metastatic breast carcinoma, J. Nucl. Med. 16, 996–1001 (1975).
J.A. Neifeld, J.N. Ingle, D.C. Tormey, M.E. Lippman, S.D. Richman, and L.L. Michaelis, Mediastinoscopy: A diagnostic aid in metastatic carcinoma of the breast, Cancer 37, 1973–1976 (1976).
T.L. Dao and T. Nemoto, The clinical significance of skin recurrence after radical mastectomy in women with cancer of the breast, Surg. Gynecol. Obstet. 117, 447–453 (1963).
A.N. Papaioannou, F.J. Tanz, and H. Volk, Fate of patients with recurrent carcinoma of the breast; recurrence five or more years after initial treatment, Cancer 20, 371–376 (1967).
J. Bruce, D.C. Carter, and J. Fraser, Patterns of recurrent disease in breast cancer, Lancet 1, 433–435(1970).
D.S. Martin and R.A. Fugmann, Clinical implications of the interrelationship of tumor size and chemotherapeutic response, Ann. Surg. 151, 97–100 (1960).
F.M. Schabel, Jr., Concepts for systemic treatment of micrometastases, Cancer 35, 15–24 (1975).
J.J. van Dyk and G. Falkson, Extended survival and remission rates in metastatic breast cancer, Cancer 27, 300–303 (1971).
R.V. Smalley, S. Murphy, Y.K. Chan, and C.M. Huguley, Comparison of two five-drug regimes vs. sequential chemotherapy in metastatic breast carcinoma, Cancer Chemother. Rep. 57, 110 (1973).
H.E. Skipper and F.M. Schabel, Jr., Quantitative and cytokinetic studies in experimental tumor systems, in: Cancer Medicine (J. Holland and E. Frei, III, eds.), 2nd Edition, Lea and Febiger, Philadelphia (1977), in press.
A. Howard and S.R. Pelc, Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relationship to chromosome breakage, Heredity 6 (Suppl.), 261–273 (1953).
G.P. Wheeler and L. Simpson-Herren, Effects of purines, pyrimidines, nucleosides and chemically related compounds on the cell cycle, in: Drugs and the Cell Cycle (A.M. Zimmerman, G.M. Padilla, and I.L. Cameron, eds.), pp. 250–306, Academic Press, New York (1973).
P. Calabresi and R.E. Parks, Chemotherapy of neoplastic diseases, in: The Pharmacological Basis of Therapeutics (L.S. Goodman and A. Gilman, eds.), 4th ed., pp. 1348–1396, Macmillan, London (1970).
P. Brookes, Reaction of alkylating agents with nucleic acids, in: Chemotherapy of Cancer (P.A. Plattner, ed.), pp. 32–43, Elsevier, Amsterdam (1964).
J.S. Johnson, J.G. Armstrong, M. Gorman, and J.P. Burnett, The vinca alkaloids: a new class of oncolytic agents, Cancer Res. 23, 1390–1427 (1963).
S.K. Carter and M. Slavik, Chemotherapy of cancer, Annu. Rev. Pharmacol. 14, 157–183 (1974).
H. Umezawa, M. Ishizuka, K. Maeda, and T. Takeuchi, Studies on bleomycin, Cancer 20, 891–895 (1967).
W.R. Bruce, B.E. Meeker, and F.A. Valeriote, Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo, J. Natl. Cancer Inst. 37, 233–245 (1966).
F. Valeriote and L. van Putten, Proliferation-dependent cytotoxicity of anticancer agents: A review, Cancer Res. 35, 2619–2630 (1975).
W.S. Wilcox, D.R. Griswold, W.R. Laster Jr., F.M. Schabel, Jr., and H.E. Skipper, Experimental evaluation of potential anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors, Cancer Chemother. Rep. 47, 27–39 (1965).
H.E. Skipper, Kinetics of mammary tumor cell growth and implications for therapy, Cancer 28, 1479–1499 (1971).
G.G. Steel, Cytokinetics of neoplasia, in: Cancer Medicine (J. Holland and E. Frei III, eds.), pp. 125–139, Lea and Febiger, Philadelphia (1973).
A.K. Laird, Dynamics of tumor growth, Br. J. Cancer 18, 490–502 (1964).
W.S. Wilcox, The last surviving cancer cell: the changes of killing it, Cancer Chemother. Rep. 50, 541–542 (1966).
M.C. Berenbaum, The last surviving cancer cell: the changes of killing it, Cancer Chemother. Rep. 52, 539–541 (1968).
M.C. Berenbaum, Dose-response curves for agents that impair cell reproductive integrity. The relation between dose-response curves and the design of selective regimens in cancer chemotherapy, Br. J. Cancer 23, 434–445 (1969).
A.A. Sandberg and G.E. Moore, Examination of blood for tumor cells, J. Natl. Cancer Inst. 19, 1–11 (1957).
E. Philippe and Y. LeGal, Growth of seventy-eight recurrent mammary cancers; quantitative study, Cancer, 21, 461–467 (1968).
Y.N. Lee and J.S. Spratt, Rate of growth of soft tissue metastases of breast cancer, Cancer 29, 344–348 (1972).
E.P. Malaise, N. Chavaudra, A. Charbit, and M. Tubiana, Relationship between the growth rate of human metastases, survival and pathological type, Eur. J. Cancer 10, 451–459 (1974).
L.M. Schiffer and P.G. Braunschweiger, Cytokinetics of human breast cancer, primary vs. metastatic lesions, Proc. Am. Assoc. Cancer Res. 17, 238 (1976).
R.C. Young and V.T. DeVita, The effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210, Cancer Res. 30, 1789–1794 (1970).
D.S. Martin, R.A. Fugmann, R.L. Stolfi, and P.E. Hayworth, Solid tumor animal model therapeutically predictive for human breast cancer, Cancer Chemother. Rep. 5, 89–110 (1975).
D.P. Griswold, Jr., The potential for murine tumor models in surgical adjuvant chemotherapy, Cancer Chemother. Rep. 5, 187–204 (1975).
A.E. Bogden, H.J. Esber, D.J. Taylor, and J.H. Gray, Comparative study on the effects of surgery, chemotherapy and immunotherapy, alone and in combination, on metastases of the 13762 mammary adenocarcinoma, Cancer Res. 34, 1627–1631, (1974).
S.I. Detre, A.J.S. Davies, and T.A. Connors, New models for cancer chemotherapy, Cancer Chemother. Rep. 5, 133–144 (1975).
B.C. Giovanella, J.S. Stëhlin, and L.J. Williams, Jr., Heterotransplantation of human malignant tumor in nude thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors, J. Natl. Cancer Inst. 52, 921–930 (1974).
E.S. Greenwald, Cancer Chemotherapy, 2nd ed., pp. 28–346, Medical Outline Series, Medical Examination Publishing Co., Inc., New York (1973).
B.A. Chabner, C.E. Myers, C.N. Coleman, and D.G. Johns, The clinical pharmacology of antineoplastic agents, N. Engl. J. Med. 292, 1107–1113 and 1159–1168 (1975).
E. Mihich, Pharmacologic principles and the basis of selectivity of drug action, in: Cancer Medicine (J. Holland and E. Frei, III, eds.), pp. 650–674, Lea and Febiger, Philadelphia (1973).
P.R. Bergevin, D.C. Tormey, and J. Blom, Guide to the use of cancer chemotherapeutic agents, Mod. Treat. 9, 185–273 (1972).
L.E. Broder and P.P. Carbone, Pharmacokinetic considerations in the design of optimal chemotherapeutic regimens for the treatment of breast carcinoma: a conceptual approach, Med. Pediatr. Oncol. 2, 11–27 (1976).
R.A. Minow, R.S. Benjamin, and J.A. Gottlieb, Adriamycin (NSC 123127) cardiomyopathy—an overview with determination of risk factors, Cancer Chemother. Rep. 6, 195–201 (1975).
J.J. Rinehart, R.P. Lewis, and S.P. Balcerzak, Adriamycin cardiotoxicity in man, Ann. Intern. Med. 81, 475–478 (1974).
D.L. Ahmann, H.F. Bisel, R.G. Hahn, R.T. Eagan, J.H. Edmonson, J.L. Steinfeld, D.C. Tormey, and W.F. Taylor, An analysis of a multiple drug program in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphamide and prednisone with or without vincristine, Cancer 36, 1925–1935 (1975).
S.K. Carter, Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy program of the NCI, in: The Design of Clinical Trials (M. Staquet, ed.), pp. 242–291, Futura Publishing Co., Mt. Kisco, New York (1972).
H.E. Skipper, Kinetic considerations associated with therapy of solid tumors, in: The Proliferation and Spread of Neoplastic Cells (University of Texas, M.D. Anderson Symposium, 1967), pp. 213–234, Williams and Wilkins, Baltimore (1968).
R.W. Talley, V.K. Vaitkevicius, and G.A. Leighton, Comparison of cyclophosphamide and 5-fluorouracil in the treatment of patients with metastatic breast cancer, Clin. Pharmacol. Ther. 6, 740–748 (1965).
Eastern Cooperative Group in Solid Tumor Chemotherapy, Comparison of antimetabolites in the treatment of breast and colon cancer, J. Am. Med. Assoc. 200, 770–778 (1967).
D.C. Tormey, Adriamycin in breast cancer: an overview of studies, Cancer Chemother. Rep. 6, 319–327(1975).
S.G. Taylor, G.P. Canellos, P. Band, and S. Pocock, Combination chemotherapy for advanced breast cancer: Randomized comparison with single drug therapy, Proc. Am. Soc. Clin. Oncol. 15, 175 (1974).
L.M. Baker, C.B. Vaughn, M. Al-Sarrof, M.L. Reed, and V.K. Vaitkevicius, Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer, Cancer 33, 513–518 (1974).
P. Band, D. Tormey, and M. Bauer, Unpublished observations from Eastern Cooperative Oncology Group trials (1976).
D. Ahmann, T. Dao, and J. Horton, Personal communication (1976).
M. DeLena, C. Brambilla, A. Morabito, and G. Bonadonna, Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer, Cancer 35, 1108–1115 (1975).
L. Simpson-Herren and D.P. Griswold, Jr., Studies of the cell population kinetics of induced and transplanted mammary adenocarcinoma in rats, Cancer Res. 33, 2415–2424 (1973).
I.S. Goldenberg, N. Sedransk, H. Volk, A. Segaloff, R.M. Kelley, and C.R. Haines, Combined androgen and antimetabolite therapy of advanced female breast cancer; a report of the Cooperative Breast Cancer Group, Cancer 36, 308–310 (1975).
F.D. Moore, S.B. Vandevanter, C.M. Boyden, J. Lokich, and R.E. Wilson, Adrenalectomy with chemotherapy in the treatment of advanced breast cancer: Objective and subjective response rates; duration and quality of life, Surgery 76, 376–388 (1974).
I.S. Goldenberg, Secondary chemotherapy of advanced breast cancer, Cancer 31, 660–663 (1973).
P.B. Stott, L. Zelkowitz, and W.G. Tucker, Combination chemohormonal therapy for disseminated breast carcinoma, Cancer Chemother. Rep. 57, 106 (1973).
E.M. Greenspan, Regression of metastatic hepatomegaly from mammary carcinoma. Cytotoxic combination chemotherapy with 5-FU, N.Y. State J. Med. 64, 2442–2449 (1964).
T. Nemoto, J. Horton, T. Cunningham, R. Sponzo, D. Rosner, R. Diaz, and T.L. Dao, Update report. Comparison of combination chemotherapy vs. adriamycin vs. adrenalectomy in breast cancer, Proc. Am. Assoc. Cancer Res. 16, 46 (1975).
G. Falkson and L. Leone, Personal communication (1976).
C. Alford, A.C. Hollinshead, and R.B. Herberman, Delayed cutaneous hypersensitivity reactions to extracts of malignant and normal human breast cells, Ann. Surg. 178, 20–24 (1973).
A.C. Hollinshead, W.T. Jaffurs, L.K. Alpert, J.E. Harris, and R.B. Herberman, Isolation and identification of soluble skin reactive membrane antigens of malignant and normal breast cells, Cancer Res. 34, 2961–2968 (1974).
M.M. Black, H.P. Leis, Jr., B. Shore, and R.E. Zachrau, Cellular hypersensitivity to breast cancer; assessment by a leukocyte migration procedure, Cancer 33, 952–958 (1974).
R.B. Herberman, Cellular immunity to human tumor associated antigens, Isr. J. Med. Sci. 9, 300–307(1973).
J.H. Dean, J.S. Silva, J.L. McCoy, C.M. Leonard, M. Middleton, G.B. Cannon, and R.B. Herberman, Lymphocyte blastogenesis induced by potassium chloride extracts of allogeneic breast carcinoma and lymphoid cells, J. Natl. Cancer Inst. 54, 1295–1298 (1975).
M.M. Black and H.P. Leis, Jr., Human breast carcinoma. Part III. Cellular responses to autologous breast cancer: Skin-window procedure, N.Y. State J. Med. 70, 2583–2589 (1970).
T.J. Cunningham, D. Daut, P.E. Wolfgang, M. Mellyn, S. Maciolek, R.W. Sponzo, and J. Horton, A correlation of DNCB-induced delayed cutaneous hypersensitivity reactions and the course of disease in patients with recurrent breast cancer, Cancer 37, 1696–1700 (1976).
M.M. Black and H.P. Leis, Jr., Cellular responses to autologous breast cancer tissue; correlation with stage and lymphoreticuloendothelial reactivity, Cancer 28, 263–273 (1971).
S.J. Cutler, C. Zippin, and A.J. Asire, The prognostic significance of palpable lymph nodes in cancer of the breast, Cancer 23, 243–250 (1969).
R.L. Stolfi, R.A. Fugmann, L.M. Stolfi, and D.S. Martin, Synergism between host anti-tumor immunity and combined modality therapy against murine breast cancer, Int. J. Cancer 13, 389–403 (1974).
B. Fisher, N. Wolmark, E. Saffer, and E.R. Fisher, Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors, Cancer 35, 134–143 (1975).
L. Israel, A randomized study of chemotherapy versus chemotherapy with Corynebacterium parvum in advanced breast cancer, in: Proceedings XI International Cancer Congress (P. Bucalossi, U. Veronesi, and N. Cascinelli, eds.), Vol. 6, pp. 77–79, Excerpta Medica, Amsterdam (1975).
J.U. Gutterman, G.R. Blumenschein, G. Hortobagyi, G. Mavligit, and E.M. Hersh, Immunotherapy for breast cancer, Breast, Diseases of the Breast 2, 29–34 (1976).
A.F. Rojas, E. Mickiewicz, J.N. Feierstein, H. Glait, and A.J. Olivari, Levamisole in advanced human breast cancer, Lancet 1, 211–215 (1976).
B. Fisher, P.P. Carbone, S.G. Economou, R. Frelick, A. Glass, H. Lerner, C. Redmond, M. Zelen, D.L. Katrych, N. Wolmark, P. Band, and E.R. Fisher, 1-Phenylalanine mustard (1-PAM) in the management of primary breast cancer: A report of early findings. N. Engl. J. Med. 292, 117–122 (1975).
G. Bonadonna, P. Valagussa, and U. Veronesi, Results of ongoing trials with adjuvant therapy in operable breast cancer, in: Breast Cancer: Trends in Research and Treatment; A Monograph of the European Organization for Research on Treatment of Cancer (J.C. Heuson, W.H. Matthiem, and M. Rozencweig, eds.), pp. 239–258, Raven Press, New York (1976).
K.W. Brunner, R.W. Sonntag, G. Martz, H.J. Senn, P. Obrecht, and P. Alberto, A controlled study in the use of combined drug therapy for metastatic breast cancer, Cancer 36, 1208–2119 (1975).
D.C. Tormey, J. Bull, C. Falkson, P. Band, and J. Blom, Adriamycin and dibromodulcitol in metastatic breast cancer, Proc. Am. Assoc. Cancer Res. 16, 129 (1975).
E.B. van Eden, G. Falkson, A.M. van der Merwe, J.J. Van Dyk, and H.C. Falkson, FIVB—A new combination of drugs in the treatment of cancer, S. Afr. Med. J. 47, 982–984 (1973).
C.A. Presant, J.F. Kolhouse, and C. Klahr, Adriamycin, 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU-NSC 409462) and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors, Cancer 37, 620–628 (1976).
D.C. Tormey, Unpublished data (1976).
P. Longacre, T. Cunningham, K. Olson, J. Horton, and R. Sponzo, HOM chemotherapy in advanced neoplasms, Proc. Am. Assoc. Cancer Res. 17, 99 (1976).
R. Zucali, C. Uslenghi, R. Kenda, and G. Bonadonna, Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy, Cancer 37, 1422–1431 (1976).
M. DeLena, L. Brugnatelli, C. Uslenghi, R. Zucali, and G. Bonadonna, Combined chemotherapy and radiotherapy in inoperable (T3bT4) breast cancer, Proc. Am. Assoc. Cancer Res. 16, 273 (1975).
A. Bennett, A.M. McDonald, J.S. Simpson, and I.F. Stamford, Breast cancer, prostaglandins and bone metastases, Lancet 1, 1218–1220 (1975).
T.J. Powles, S.A. Clark, D.M. Easty, G.C. Easty, and A.M. Neville, The inhibition by aspirin and indomethacin of osteolytic tumour deposits and hypercalcaemia in rats with Walker tumour and its possible application to human breast cancer, Br. J. Cancer 28, 316–321(1973).
T. Powles, Personal communication (1975).
J.R. Little, A.J.D. Dale, and H. Okazuki, Meningeal carcinomatosis: clinical manifestations, Arch. Neurol 30, 138–143 (1974).
M.E. Olson, N.L. Chernik, and J.B. Posner, Infiltration of the leptomeninges by systemic cancer—a clinical and pathologic study, Arch. Neurol. 30, 122–137 (1974).
S. Kaufman and M. Goldstein, Combination chemotherapy in disseminated carcinoma of the breast, Surg. Gynecol. Obstet. 137, 83–86 (1973).
B.J. Kennedy and A.S. Gilbertson, Increased erythropoiesis induced by androgenic hormone therapy, N. Engl. J. Med. 256, 719–726 (1957).
P.P. Carbone, V. Bono, E. Frei, and C.O. Brindley, Clinical studies with vincristine, Blood 21, 640–647 (1963).
N.V. Dimitrov, S. Andre, G. Eliopoulos, and B. Halpern, Effect of Corynebacterium parvum on animal and human bone marrow cultures, Proc. Am. Assoc. Cancer Res. 16, 151 (1975).
J.M. Baron and J.E. Ultmann, The management of malignant serous effusions, in: Chemotherapy of Malignant Neoplasms (F.J. Ansfield, ed.), pp. 126–145, Charles C. Thomas, Springfield, Illinois (1973).
C.B. Anderson, G.W. Philpott, and T.B. Ferguson, The treatment of malignant pleural effusions, Cancer 33, 916–922 (1974).
R.M. Rubinson and H. Bolooki, Intrapleural tetracycline for control of malignant pleural effusion: A preliminary report, South. Med. J. 65, 847–849 (1972).
G.F. Robbins, J. Shah, P. Rosen, F. Chu, and J. Taylor, Inflammatory carcinoma of the breast, Surg. Clin. North Am. 54, 801–810 (1974).
D.L. Ellis and S.L. Teitelbaum, Inflammatory carcinoma of the breast; a pathological definition, Cancer 33, 1045–1047 (1974).
J.T. Corail and T.L. Dao, The etiology of inflammatory reactions in breast carcinoma, Surg. Forum 9, 611–614 (1958).
C.C. Wang, Management of inflammatory carcinoma of the breast, J. Am. Med. Assoc. 201, 533 (1967).
R.M. Yonemoto, J.L. Keating, R.L. Byron, and D.M. Reihiwaki, Inflammatory carcinoma of the breast treated by bilateral adrenalectomy, Surgery 68, 461–467 (1970).
T.L. Dao and J.D. McCarthy, Treatment of inflammatory carcinoma of the breast, Surg. Gynecol. Obstet. 105, 289–294 (1957).
C.C. Harris, The carcinogenicity of anticancer drugs: A hazard in man, Cancer 37, 1014–1023 (1976).
I. Penn, Second malignant neoplasms associated with immunosuppressive medications, Cancer 37, 1024–1032 (1976).
G.T. Ross, Congenital anomalies among children born of mothers receiving chemotherapy for gestational trophoblastic neoplasms, Cancer 37, 1043–1047 (1976).
D.H. Russell, B.G.M. Durie, and S.E. Salmon, Polyamines as predictors of success and failure in cancer chemotherapy, Lancet 2, 797–799 (1975).
T.P. Waalkes, C.W. Gehrke, W.A. Bleyer, R.W. Zumwalt, C.L.M. Olweny, K.C. Kao, D.B. Lakings, and S.A. Jacobs, Potential biologic markers in Burkitt’s lymphoma, Cancer Chemother. Rep. 59, 721–727 (1975).
D.C. Tormey and T.P. Waalkes, Biochemical markers in cancer of the breast, Recent Results Cancer Res. 57, 78–94 (1976).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1977 Springer Science+Business Media New York
About this chapter
Cite this chapter
Carbone, P.P., Tormey, D.C. (1977). Combination Chemotherapy for Advanced Disease. In: McGuire, W.L. (eds) Current Approaches to Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0480-8_4
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0480-8_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0482-2
Online ISBN: 978-1-4757-0480-8
eBook Packages: Springer Book Archive